Editorial of Harnessing the Power of T Cells: The Promising Hope for a Universal Influenza Vaccine

<p dir="ltr">The global burden of influenza-associated respiratory mortality is higher than previous estimates, with over 0.6 million deaths per year and additional mortality rates attributed to non-respiratory but influenza-related illnesses [1]. Numerous vaccines have been developed to protect against influenza infections. However, the efficacies of current influenza vaccines, which include cell-based vaccines, recombinant vaccines, inactivated influenza vaccine (IIV) and live attenuated influenza vaccine (LAIV) have dropped in recent years and do not provide long-term viral defense. Moreover, the hemagglutination inhibition (HAI) titers are widely considered to correlate with protection against influenza; however, patients with high titers have also been infected by influenza, while others without titers were protected [2]. Therefore, there is a real need to explore novel candidates of vaccine development and decrease mortality rates.</p><h2>Other Information</h2><p dir="ltr">Published in: Vaccines<br>License: <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank">https://creativecommons.org/licenses/by/4.0/</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.3390/vaccines8030376" target="_blank">https://dx.doi.org/10.3390/vaccines8030376</a></p>